The stock of VBI Vaccines Inc. (VBIV) has seen a -15.33% decrease in the past week, with a 15.08% gain in the past month, and a 8.37% flourish in the past quarter. The volatility ratio for the week is 11.33%, and the volatility levels for the past 30 days are at 8.05% for VBIV.. The simple moving average for the past 20 days is -5.19% for VBIV’s stock, with a 6.37% simple moving average for the past 200 days.
Is It Worth Investing in VBI Vaccines Inc. (NASDAQ: VBIV) Right Now?
VBIV has 36-month beta value of 2.18. Analysts have mixed views on the stock, with 3 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for VBIV is 25.69M, and currently, short sellers hold a 1.62% ratio of that float. The average trading volume of VBIV on July 19, 2024 was 140.22K shares.
VBIV) stock’s latest price update
VBI Vaccines Inc. (NASDAQ: VBIV) has experienced a decline in its stock price by -9.59 compared to its previous closing price of 0.73. However, the company has seen a fall of -15.33% in its stock price over the last five trading days. businesswire.com reported 2024-06-25 that CAMBRIDGE, Mass.–(BUSINESS WIRE)–VBI Vaccines Inc. (Nasdaq: VBIV) (“VBI” or the “Company”), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced the voting results from its annual general meeting of shareholders held on June 25, 2024 (the “Meeting”). The total number of common shares of the Company (“Common Shares”) represented by shareholders (“Shareholders”) present in person or represented by proxy at the Meeting w.
Analysts’ Opinion of VBIV
Many brokerage firms have already submitted their reports for VBIV stocks, with Raymond James repeating the rating for VBIV by listing it as a “Outperform.” The predicted price for VBIV in the upcoming period, according to Raymond James is $2 based on the research report published on November 11, 2022 of the previous year 2022.
Jefferies, on the other hand, stated in their research note that they expect to see VBIV reach a price target of $6, previously predicting the price at $7. The rating they have provided for VBIV stocks is “Buy” according to the report published on December 29th, 2021.
Jefferies gave a rating of “Buy” to VBIV, setting the target price at $7 in the report published on February 25th of the previous year.
VBIV Trading at 1.96% from the 50-Day Moving Average
After a stumble in the market that brought VBIV to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -56.94% of loss for the given period.
Volatility was left at 8.05%, however, over the last 30 days, the volatility rate increased by 11.33%, as shares surge +10.85% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +10.02% upper at present.
During the last 5 trading sessions, VBIV fell by -15.33%, which changed the moving average for the period of 200-days by -0.93% in comparison to the 20-day moving average, which settled at $0.6994. In addition, VBI Vaccines Inc. saw 12.34% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for VBIV
Current profitability levels for the company are sitting at:
- -7.56 for the present operating margin
- -0.29 for the gross margin
The net margin for VBI Vaccines Inc. stands at -8.82. The total capital return value is set at 33.08. Equity return is now at value -419.59, with -81.40 for asset returns.
Based on VBI Vaccines Inc. (VBIV), the company’s capital structure generated 1.12 points at debt to capital in total, while cash flow to debt ratio is standing at -0.99. The debt to equity ratio resting at -9.28. The interest coverage ratio of the stock is -99.66.
Currently, EBITDA for the company is -53.32 million with net debt to EBITDA at -0.76. When we switch over and look at the enterprise to sales, we see a ratio of 6.06. The receivables turnover for the company is 5.42for trailing twelve months and the total asset turnover is 0.12. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.34.
Conclusion
To put it simply, VBI Vaccines Inc. (VBIV) has had a mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
